Apimeds Pharmaceuticals US, Inc. AI Stock Analysis
Want to see APUS full AI Analyst Report?
Apimeds Pharmaceuticals US, Inc. (APUS) AI Stock Analysis
Apimeds Pharmaceuticals US, Inc.
(NYSE MKT:APUS)
The score is pressured primarily by weak financial performance (heavy losses and ongoing cash burn despite only modest early revenue) and a clearly bearish technical trend with negative momentum. Valuation metrics provide limited support due to negative earnings and no dividend. Corporate events are a modest positive, reflecting strategic expansion and strengthened finance leadership, but they are not yet reflected in the core financials.
Apimeds Pharmaceuticals US, Inc. (APUS) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $2.41M
- Dividend Yield
- ―
- Average Volume (3M)
- 3.72M
- Price to Earnings (P/E)
- -0.1
- Beta (1Y)
- 2.44
- Revenue Growth
- ―
- EPS Growth
- -377.99%
- Country
- US
- Employees
- 7
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
Apimeds Pharmaceuticals US, Inc. Business Overview & Revenue Model
Company Description
Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Insc...
Apimeds Pharmaceuticals US, Inc. Financial Statement Overview
Summary
Overall fundamentals skew weak despite a relatively supportive balance sheet. Revenue only recently emerged (TTM ~$2.9M) and profitability is far from break-even with very large operating and net losses (net margin around -785%). Cash flow is also a key drag with continued negative operating and free cash flow (~-$11.8M TTM), implying ongoing financing needs. Offsetting this, leverage is low (debt-to-equity ~0.07) and equity is sizable (~$140.5M), providing near-term flexibility.
Income Statement
18Very NegativeBalance Sheet
64PositiveCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.90M | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 2.82M | -5,706 | 0 | 0 | 0 | 0 |
| EBITDA | -25.12M | -5.71M | -1.27M | -739.63K | -639.53K | -1.02M |
| Net Income | -22.74M | -6.00M | -1.39M | -777.69K | -668.67K | -1.03M |
Balance Sheet | ||||||
| Total Assets | 153.53M | 164.18M | 13.06K | 422.08K | 6,171 | 172.17K |
| Cash, Cash Equivalents and Short-Term Investments | 17.91K | 3.64M | 3,455 | 410.48K | 6,171 | 171.44K |
| Total Debt | 9.61M | 7.76M | 596.84K | 266.89K | 660.00K | 400.00K |
| Total Liabilities | 13.01M | 10.84M | 1.37M | 390.20K | 719.78K | 410.65K |
| Stockholders Equity | 140.52M | 153.35M | -1.36M | 31.87K | -713.61K | -238.48K |
Cash Flow | ||||||
| Free Cash Flow | -11.80M | -8.98M | -733.53K | -627.79K | -448.17K | -823.11K |
| Operating Cash Flow | -11.77M | -8.93M | -733.53K | -627.79K | -448.17K | -823.11K |
| Investing Cash Flow | -8.09M | -10.06M | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 12.89M | 20.62M | 326.50K | 1.03M | 282.90K | 400.00K |
Apimeds Pharmaceuticals US, Inc. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APUS, the sentiment is Negative. The current price of 1.60 is below the 20-day moving average (MA) of 2.55, below the 50-day MA of 3.39, and below the 200-day MA of 9.73, indicating a bearish trend. The MACD of -0.52 indicates Positive momentum. The RSI at 27.86 is Positive, neither overbought nor oversold. The STOCH value of 6.56 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for APUS.
Apimeds Pharmaceuticals US, Inc. Peers Comparison
Overall Rating
AYTU55Neutral
CPIX53Neutral
APUS44.2Neutral
SNOA43Neutral
YCBD43Neutral
BFRI40Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 55Neutral | $28.91M | -1.49 | -69.19% | ― | -8.12% | 7.24% | |
| 53Neutral | $94.47M | 1.27 | 202.58% | 23.73% | -39.11% | -241.27% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 44Neutral | $3.21M | -0.10 | -17.27% | ― | ― | -377.99% | |
| 43Neutral | $4.10M | -0.79 | -36.40% | ― | 38.69% | 58.68% | |
| 43Neutral | $4.25M | -1.17 | -34.25% | ― | 10.01% | 95.01% | |
| 40Underperform | $10.23M | -1.32 | -110.30% | ― | 29.85% | 78.56% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| APUS | Apimeds Pharmaceuticals US, Inc. | 1.60 | -18.70 | -92.12% | |
| SNOA | Sonoma Pharmaceuticals, Inc. | 0.72 | -2.49 | -77.51% | |
| AYTU | Aytu BioScience | 2.66 | 0.60 | 29.13% | |
| CPIX | Cumberland Pharmaceuticals Inc. | 5.84 | 4.23 | 263.86% | |
| YCBD | Cbdmd INc | 0.36 | -0.16 | -30.77% | |
| BFRI | Biofrontera, Inc. | 0.53 | -0.26 | -33.25% |
Apimeds Pharmaceuticals US, Inc. Corporate Events
Apimeds Subsidiary Expands Into On-Chain Insurance Services
PositiveOn Oct. 4, 2026, MindWave Innovations Inc., a subsidiary of Apimeds Pharmaceuticals US, Inc., signed a two-year master maintenance and service agreement with Delaware-based BlockAssure Inc. to build, deploy and operate AssureChain, a dedicated subnet...
Apimeds Pharmaceuticals Appoints Eric Sherb as New CFO
PositiveApimeds Pharmaceuticals US, Inc. announced that on September 29, 2026, Interim Chief Financial Officer Erick Frim resigned effective immediately, with the company stating his departure did not stem from any disagreement over operations, policies, or...
MindWave expands blockchain services into sports media markets
PositiveOn September 24, 2026, MindWave Innovations Inc., a subsidiary of Apimeds Pharmaceuticals US, Inc., entered a 12‑month strategic technology services agreement with Singapore-based AQUAE Holdings to deploy its MindChain blockchain as the core infrastr...
Apimeds Pharmaceuticals Executes Reverse Stock Split and Amendments
NeutralApimeds Pharmaceuticals US, Inc. implemented a one-for-ten reverse stock split of its issued and outstanding common stock, effective July 24, 2026, following stockholder approval obtained on December 1, 2025. In connection with the transaction, the c...
Apimeds Restructures Board and Appoints New Director
NeutralOn September 10, 2026, Apimeds Pharmaceuticals US, Inc. and its affiliated parties executed a first amendment to their April 24, 2026 confidential settlement and mutual release agreement, restructuring the composition of the company’s board of direct...
Apimeds Secures Key Apitox Rights via FreeT Agreement
PositiveOn August 19, 2026, Apimeds Pharmaceuticals US, Inc. entered into an Assignment and Transfer Agreement with Korea-based FreeT Inc. under which FreeT irrevocably assigned Apimeds its Apitox-related rights originally acquired in 2015. These Assigned Ri...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Nov 20, 2026
